The Molecular Oncology Almanac: Assertion Details

Assertion: Sensitivity to Elimusertib (in Any solid tumor)
Clinical trial

Somatic Variant: ATM (Nonsense)

The ATR inhibitor BAY 1895344 was tolerated in a dose-escalation phase 1 trial (NCT03188965) across 21 patients with advanced solid tumors. Responders had ATM protein loss and/or deleterious ATM variants.

Citations:

Yap TA, Tan DSP, Terbuch A, et al. First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors. Cancer Discovery. 2021;11(1):80-91.

Assertion: Sensitivity to Elimusertib (in Any solid tumor) Clinical trial

Clinical trial

Assertion: Sensitivity to Elimusertib (in Any solid tumor)
Clinical trial